Gain Therapeutics

Gain Therapeutics Presents Topline Data from P-I Clinical Evaluation of GT-02287 to Treat Parkinson’s Disease #gaintherapeutics #gt02287 #parkinsondisease #clinicaltrial #phase1 #safety #tolerability #cerebrospinalfluid #gba1mutation

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for #Parkinson’s Disease https://lnkd.in/eeQVTVDZ

Meet our Dr. Joanne Taylor Drug Discovery World's Megan Thomas looks at a day in the life of Dr. Joanne Taylor, Senior Vice President and Head of Discovery Research at Gain Therapeutics. #DrugDiscovery #Neuroscience #Research https://lnkd.in/eDXUz-Sk

Nearly one million people in the U.S. are living with #Parkinson's disease, with nearly 90K being diagnosed in the US each year, according to the Parkinson's Foundation. There is currently no cure for the disease but there are a number of promising treatments in development such as our GT-02287 in which we recently announced the successful completion of the SAD/MAD in 72 healthy subjects with no serious adverse events or discontinuations related to adverse events and the ability to achieve therapeutic plasma levels with oral dosing further confirm our belief in GT-02287’s potential to be a transformative therapy for Parkinson’s disease patients. #neurodegenerative #drugdiscovery Find out more about it at the link below: https://lnkd.in/gHUJPjpS

#ICYMI Gain Therapeutics Interim CEO Gene Mack speaks with Ram Selvaraju at H.C. Wainwright & Co., LLC’s Annual Neuro Perspectives Virtual Conference https://lnkd.in/eehbxZzH

Thank you for the coverage PharmaVoice. https://lnkd.in/eFxqAwSV

Gain Therapeutics reports financial results for Second Quarter 2024 and provides corporate update. "...we eagerly await the full topline results from the MAD part of the study expected this month . . . [and] look forward to presenting our findings at medical conferences this fall and advancing GT-02287 into a Phase 1b study . . . in the fourth quarter of 2024" stated Interim CEO and current CFO Gene Mack. Read the full press release here: https://lnkd.in/g4sgh44S

Gain Therapeutics is looking forward to participating in BTIG’s Virtual Biotechnology Conference 2024. Join interim-CEO Gene Mack and Chief Medical Officer Jonas Hannestad for their fireside chat with Tom Shrader on August 6th at 4pm ET. To attend the conference, email uscorporateaccess@btig.com

Nearly one million people in the U.S. are living with #Parkinson's disease, with nearly 90K being diagnosed in the US each year, according to the Parkinson's Foundation. There is currently no cure for the disease but there are a number of promising treatments in development such as our GT-02287 in which we recently announced the successful completion of the SAD/MAD in 72 healthy subjects with no serious adverse events or discontinuations related to adverse events and the ability to achieve therapeutic plasma levels with oral dosing further confirm our belief in GT-02287’s potential to be a transformative therapy for Parkinson’s disease patients. #neurodegenerative #drugdiscovery Find out more about it at the link below: https://lnkd.in/gHUJPjpS

Gain Therapeutics' GT-02287 is a clinical stage program that has the potential to treat dementia with Lewy bodies (DLB). DLB is a type of dementia that causes a decline in memory, thinking, and behavior. In DLB, protein deposits called Lewy bodies accumulate in neuronal cells. In preclinical models, GT-02287 has been shown to reduce the aggregation of α-synuclein, a protein found in Lewy bodies. https://lnkd.in/ev8ixUCm